Dr. Gullbo was trained at Uppsala Academic Hospital in Sweden and is specialized in Medical Oncology and Clinical Pharmacology. During 2015-2017 (prior to joining Theradex Oncology) he served as the hospital’s Head of Oncology unit leading clinical recruitment and development as well as 35 full-time medical oncologists. Joachim also served as CMO, Advisor and founder of several biotech companies in Sweden.
Joachim holds a Doctor of Philosophy (PhD) degree in Clinical Pharmacology from Uppsala University, Sweden; Doctor of Medicine (MD), Uppsala University, Faculty of Medicine, Uppsala, Sweden; and a Master of Science (MSc) in Pharmacy, Uppsala University, Faculty of Pharmacy, Uppsala, Sweden.
As an academic researcher, Joachim has authored/co-authored over 85 peer-reviewed scientific publications, all publications available at https://www.ncbi.nlm.nih.gov/pubmed/?term=gullbo.
At Theradex, Dr. Gullbo works closely with sponsors for clinical drug development, including protocol design and medical monitoring and safety review for their clinical trials. His pharmacology background enables insight for sponsors as they contemplate their clinical strategy. He also plays a primary role in identifying key opinion leaders to ensure adequacy of the program’s scientific basis and endorsement on assumptions related to medical needs and clinical utility. Joachim’s experience includes Phase I and I/II (various solid tumors including glioma and ovarian cancer, AML/MDS, myeloma); Phase II: GEJ Cancer, Breast cancer, AML/MDS, Ovarian Cancer, glioblastoma; Phase III: MDS, multiple myeloma, and (as a co-investigator also breast cancer, colorectal cancer, glioma).